Save Product
Product Details
Synonyms
TL1A, VEGI, TNFSF15
Source
Human TL1A Protein, His Tag (TLA-H5249) is expressed from human 293 cells (HEK293). It contains AA Leu 72- Leu 251 (Accession # O95150-1 ).
Predicted N-terminus: His
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the N-terminus.
The protein has a calculated MW of 22.3 kDa. The protein migrates as 27 kDa and 29-33 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Within the expressed region, several mutations were introduced to optimize the protein expression and stability.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.2 M Arginine, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Human TL1A Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
SEC-HPLC
The purity of Human TL1A Protein, His Tag (Cat. No. TLA-H5249) was greater than 90% as determined by SEC-HPLC.
Bioactivity-ELISA
Immobilized Human TL1A Protein, His Tag (Cat. No. TLA-H5249) at 1 μg/mL (100 μL/well) can bind Tulisokibart with a linear range of 0.06-2 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
Tumor necrosis factor superfamily member 15
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
18 Details
- Highest Development Stage：
Phase 3 Clinical
Contact Us
Drug Candidate Licensing
